Nanomotors are tiny machines capable of autonomous movement, which can navigate through the complex biological environment and deliver therapeutic agents to specific target sites. Among the various types of nanomotors, urease-powered nanomotors have emerged as a particularly promising approach for bladder cancer therapy. At Alfa Cytology, we enable help our clients develop urease-powered nanomotor for drug delivery in bladder cancer.

Introduction to Urease-Powered Nanomotor

Urease-powered nanomotors utilize the enzymatic activity of urease to generate propulsive forces, enabling them to move within the bladder and deliver therapeutic payloads. Urease is an enzyme that catalyzes the hydrolysis of urea into ammonia and carbon dioxide. This enzymatic reaction produces gas bubbles, which propel the nanomotors forward in a self-propelling manner.

Fig 1. Schematic illustration for intravesical delivery of urease-powered nanomotors to enhance penetration and retention in the bladder. (Choi H., et al. 2020)

One of the key advantages of urease-powered nanomotors is their ability to navigate through the urinary system, specifically the bladder. The bladder presents a challenging environment for drug delivery due to its complex structure and constant urine flow. Urease-powered nanomotors can effectively overcome these barriers and reach the tumor site, ensuring targeted drug delivery and minimizing adverse effects on healthy tissues.

Our Services

At Alfa Cytology, we are at the forefront of urease-powered nanomotor drug delivery system development for bladder cancer therapy. Our team of experienced researchers and scientists is dedicated to advancing the field of nanomedicine and revolutionizing bladder cancer therapy.

• Design and Fabrication of Urease-Powered Nanomotors
  Through meticulous engineering, we optimize the size, shape, and surface properties of the nanomotors to ensure optimal performance and minimal immunogenicity. We utilize cutting-edge nanofabrication techniques to create nanomotors with high propulsion efficiency and enhanced stability in biological fluids.

• Payload Loading and Release Strategies
  Our team utilizes advanced encapsulation techniques to ensure high drug loading capacity while maintaining stability and controlled release profiles. By incorporating stimuli-responsive materials, we can achieve site-specific drug release triggered by factors such as pH, temperature, or enzyme activity, further enhancing the therapeutic efficacy of the system.

Contact Us

At Alfa Cytology, we are committed to continuous innovation and collaboration to advance urease-powered nanomotor drug delivery systems for bladder cancer treatment. If you would like to learn more about our services or discuss potential collaborations, please contact us today to explore the possibilities of this innovative approach in bladder cancer therapy.

• Cell Membranes-Based Delivery System Development
• Chitosan-Based Delivery System Development
• Extracellular Vesicles-Based Delivery System Development
• Gel-Based Delivery System Development
• Liposomal Delivery System Development
• Metal Nanoparticles-Based Delivery System Development
• Microemulsion-Based Delivery System Development
• MSNP-Based Delivery System Development
• Polymeric Micelles Delivery System Development